澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NEUREN PHARMACEUTICALS LTD

20.140

+0.3101.56%

成交量：15.11萬

成交額：303.56萬

市值：25.51億

市盈率：17.55

高：20.230

開：19.830

低：19.675

收：19.830

52周最高：22.985

52周最低：8.610

股本：1.27億

流通股本：1.08億

量比：0.51

換手率：0.14%

股息：- -

股息率：- -

每股收益(TTM):1.148

每股收益(LYR):1.112

淨資產收益率：54.96%

總資產收益率：41.13%

市淨率：7.89

市盈率(LYR):18.12

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股-0.33%

資金流向

資金流入：

資金流出：

新聞資訊

BUZZ-澳大利亞 Neuren 公司的雷特綜合症療法獲得美國食品藥品管理局（FDA）批准，公司業績飆升

Neuren Pharmaceuticals第三季度發佈創紀錄的Daybue™淨銷售額達1.011億美元

BUZZ-澳大利亞 Neuren 製藥公司因 DAYBUE 銷量大增而創下一年新高

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/NEU.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":20.14,"timestamp":1766466720000,"preClose":19.83,"halted":0,"volume":151070,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":1.147709,"marketStatus":"已收盤","change":0.31,"latestTime":"12-23 16:12:00 AEDT","open":19.83,"high":20.23,"low":19.675,"amount":3035600,"amplitude":0.027988,"askPrice":20.16,"askSize":100,"bidPrice":20.06,"bidSize":498,"shortable":3,"etf":0,"ttmEps":1.147709,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1766530800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":19.83,"openAndCloseTimeList":[[1766444400000,1766466000000]],"volumeRatio":0.511776,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"41.13%","roe":"54.96%","lyrEps":1.111713,"volumeRatio":0.511776,"shares":126639526,"dividePrice":0,"high":20.23,"amplitude":0.027988,"preClose":19.83,"low":19.675,"week52Low":8.61,"pbRate":"7.89","psRate":"11.65","week52High":22.985,"institutionHeld":0,"latestPrice":20.14,"committee":0.665552,"eps":1.147709,"divideRate":0,"volume":151070,"delay":0,"ttmEps":1.147709,"open":19.83,"prevYearClose":12.5,"prevWeekClose":19.59,"prevMonthClose":19.64,"prevQuarterClose":19.74,"fiveDayClose":19.5,"twentyDayClose":18.61,"sixtyDayClose":19.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591984636","title":"BUZZ-澳大利亞 Neuren 公司的雷特綜合症療法獲得美國食品藥品管理局（FDA）批准，公司業績飆升","url":"https://stock-news.laohu8.com/highlight/detail?id=2591984636","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591984636?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 08:42","pubTimestamp":1765759362,"startTime":"0","endTime":"0","summary":"12月15日 - ** Neuren Pharmaceuticals NEU.AX 股价飙升3.8%至19.73澳元，创下自12月5日以来的最大盘中涨幅** 该公司称，  合作伙伴Acadia Pharmaceuticals ACAD.O获得了美国FDA对DAYBUE STIX trofinetide 口服液的批准。DAYBUE STIX 的口服溶液获得美国 FDA 批准** DAYBUE STIX 是一种粉末配方，用于治疗雷特综合症** 公司获得净销售额的特许权使用费** 截至目前，公司股价上涨了 57.6%。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4S3XL01R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK7508","NEU.AU","LU2065171402.SGD","BK7096","LU2065171311.SGD","BK4139","LU2065170008.USD","ACAD"],"gpt_icon":0},{"id":"1190129440","title":"Neuren Pharmaceuticals第三季度發佈創紀錄的Daybue™淨銷售額達1.011億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190129440","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190129440?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 00:46","pubTimestamp":1763570804,"startTime":"0","endTime":"0","summary":"11月6日 - Neuren Pharmaceuticals Ltd宣布第三季度的Daybue™净销售额创下纪录，达到1.011亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2557584096","title":"BUZZ-澳大利亞 Neuren 製藥公司因 DAYBUE 銷量大增而創下一年新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2557584096","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557584096?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 10:17","pubTimestamp":1754533072,"startTime":"0","endTime":"0","summary":"BUZZ-澳大利亚 Neuren 制药公司因 DAYBUE 销量大增而创下一年新高8月7日 - ** Neuren Pharmaceuticals NEU.AX股价上涨8.4%至18.440澳元，创下自2024年8月2日以来的最高水平。** 该药物开发商称其北美合作伙伴 Acadia Pharmaceuticals ACAD.O第二季度DAYBUE 的净销售额为9610万美元，比去年同期增长14%。** 该药用于治疗雷特综合征等遗传性脑部疾病** Neuren 预计第二季度从 DAYBUE 的销售中获得 1,470 万澳元的版税，同比增长 16** 公司已 授予 Acadia 公司开发和商业化 DAYBUE(trofinetide 的独家许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nL4S3TZ09B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACAD","LU2065171402.SGD","BK7508","NEU.AU","BK7096","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NEU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.003303}]}}